Pharma Mar SAU
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a syntheti… Read more
Pharma Mar SAU - Asset Resilience Ratio
Pharma Mar SAU (PHMMF) has an Asset Resilience Ratio of 28.37% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Pharma Mar SAU's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Pharma Mar SAU's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $97.12 Million | 28.37% |
| Total Liquid Assets | $97.12 Million | 28.37% |
Asset Resilience Insights
- Very High Liquidity: Pharma Mar SAU maintains exceptional liquid asset reserves at 28.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pharma Mar SAU Industry Peers by Asset Resilience Ratio
Compare Pharma Mar SAU's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Pharma Mar SAU (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Pharma Mar SAU.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 26.11% | $91.29 Million | $349.64 Million | -4.00pp |
| 2023-12-31 | 30.11% | $102.54 Million | $340.52 Million | +21.82pp |
| 2022-12-31 | 8.29% | $32.61 Million | $393.26 Million | -15.74pp |
| 2021-12-31 | 24.03% | $88.53 Million | $368.39 Million | -6.04pp |
| 2020-12-31 | 30.07% | $99.31 Million | $330.26 Million | +27.46pp |
| 2019-12-31 | 2.61% | $3.26 Million | $124.70 Million | -0.01pp |
| 2018-12-31 | 2.62% | $4.13 Million | $157.68 Million | -1.47pp |
| 2017-12-31 | 4.09% | $7.67 Million | $187.72 Million | -4.09pp |
| 2016-12-31 | 8.17% | $18.08 Million | $221.14 Million | -9.75pp |
| 2015-12-31 | 17.93% | $38.00 Million | $211.94 Million | +8.51pp |
| 2014-12-31 | 9.41% | $18.96 Million | $201.39 Million | +6.05pp |
| 2013-12-31 | 3.37% | $6.38 Million | $189.37 Million | -4.69pp |
| 2012-12-31 | 8.05% | $16.09 Million | $199.83 Million | -0.64pp |
| 2011-12-31 | 8.70% | $18.94 Million | $217.82 Million | -2.56pp |
| 2010-12-31 | 11.26% | $25.98 Million | $230.82 Million | -53.90pp |
| 2005-12-31 | 65.16% | $256.54 Million | $393.72 Million | +6.03pp |
| 2004-12-31 | 59.13% | $199.46 Million | $337.34 Million | -- |